NetScientific CEO hails deal with Martlet Capital as an important milestone
May 13, 2024 at 10:56 am EDT
Share
(via NewsDirect)
NetScientific PLC (AIM:NSCI) CEO Dr Ilian Iliev takes Proactive's Stephen Gunnion through a transaction that will see NetScientific company EMV Capital become the investment advisor to Martlet Capital's portfolio of 53 investments while acquiring its operational venture capital business.
Iliev said the transaction is part of NetScientific's strategic goal to become a leading deep tech and life sciences venture capital investor in the UK and Europe, employing a differentiated investment strategy characterised by proactive value creation and capital-light approaches. The deal notably expands NetScientific's assets under management by nearly doubling them with the addition of a £23 million portfolio from Marlet Capital and includes the acquisition of Martlet Capital’s operational team, forming a new entity under NetScientific.
Iliev emphasised the alignment in ethos between NetScientific and Martlet Capital, rooted in long-term relationships and mutual commitment to the sectors. He also highlighted upcoming initiatives, including the launch of new funds aimed at investing in early-stage companies and growth opportunities within the UK, specifically in the Cambridge cluster.
Contact Details
Proactive UK Ltd
+44 20 7989 0813
uk@proactiveinvestors.com
Copyright (c) 2024 TheNewswire - All rights reserved.
Copyright (c) 2024 TheNewswire - All rights reserved., source Press Releases
NetScientific plc is a United Kingdom-based deep tech and life sciences venture capital (VC) investment group with an international portfolio of innovative companies. The Company identifies, invests in, and builds high growth companies in the United Kingdom and internationally. It employs a capital-light investment approach, making use of its balance sheet and syndicating investments through its wholly owned VC subsidiary, EMV Capital Limited. The Company secures a mixture of direct equity stakes and carried interest stakes in its portfolio of companies, creating a structure that can support a large portfolio. Its portfolio consists of a combination of direct investments and capital under advisory (CUA). The Company has about 24 portfolio companies with a focus on life sciences, technology, and sustainability. The Company's subsidiaries include EMV Capital Limited, Glycotest, Inc., and ProAxsis Limited, among others.